Genetic effects of a 13q31.1 microdeletion detected by noninvasive prenatal testing (NIPT)

Yifang Jia, Heyong Zhao, Donghong Shi, Wen Peng, Luwen Xie, Wei Wang, Fuman Jiang, Hongyun Zhang, Xietong Wang
US National Library of Medicine Sep 15, 2004
In this study, aCGH was used to confirm the existence of the genomic rearrangement that was detected by NIPT to further understand its origin. Total genomic DNA was extracted from 10 ml of fetal amniotic fluid or 2 ml of uncultured venous blood samples from the parents with a commercially available Amniotic Fluid Genomic DNA Extraction Kit and a Blood Genomic DNA Extraction kit, respectively (both from BioChain Institute Inc., Newark, CA), according to the manufacturer’s instructions. As previously described, for each aCGH experiment, 400 ng of purified DNA and normal sex-matched DNA (BioChain Institute, Inc.) were digested with 10 U Alu I and 10 U Rsa I (Promega, Madison, WI, USA) and differentially labeled with cyanine-5 (cy5) and cyanine-3 (Cy3) fluorescent dyes using a Genomic DNA Enzymatic Labeling Kit (Agilent, Santa Clara, CA).”

Leave a Reply